Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

CorMedix (CRMD) Gross Margin (2016 - 2025)

Historic Gross Margin for CorMedix (CRMD) over the last 12 years, with Q3 2025 value amounting to 89.26%.

  • CorMedix's Gross Margin fell 47400.0% to 89.26% in Q3 2025 from the same period last year, while for Sep 2025 it was 92.61%, marking a year-over-year increase of 86500.0%. This contributed to the annual value of 92.66% for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, CorMedix's Gross Margin is 89.26%, which was down 47400.0% from 95.31% recorded in Q2 2025.
  • CorMedix's Gross Margin's 5-year high stood at 8322.71% during Q1 2024, with a 5-year trough of 76.12% in Q2 2021.
  • In the last 4 years, CorMedix's Gross Margin had a median value of 89.26% in 2025 and averaged 612.59%.
  • As far as peak fluctuations go, CorMedix's Gross Margin skyrocketed by 1745600bps in 2022, and later tumbled by -82268000bps in 2025.
  • Quarter analysis of 4 years shows CorMedix's Gross Margin stood at 14.88% in 2021, then skyrocketed by 563bps to 98.63% in 2022, then decreased by -2bps to 96.23% in 2024, then dropped by -7bps to 89.26% in 2025.
  • Its Gross Margin was 89.26% in Q3 2025, compared to 95.31% in Q2 2025 and 95.91% in Q1 2025.